MERZ
Merz, a global leader in medical aesthetics, today announced the launch of Belotero® Lips, with products specifically designed for lip enhancement and treatment of perioral lines. The line includes two hyaluronic acid (HA) dermal filler products that complement each other to deliver safe, effective and natural-looking cosmetic results.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180409005702/en/
Popularized by celebrities and social media influencers, the lip-filler market for female millennials is on the fast track to growth: lip beautification with hyaluronic acid fillers is currently among the most frequently requested procedures in aesthetic practices1 . Designed to appeal to a broader and more youthful target audience, the new Belotero® Lips campaign emphasizes the importance of individual beauty and emotions with the tagline “Showing off not just you - but an enhanced version of you.” Most importantly, Belotero® Lips gives aesthetic physicians more creative power with two new products that can be tailored to meet every individual patient's needs and desires.
“A single product is often not versatile enough to deliver the natural, personalized result desired by lip patients,” said Dr. Yannick Grosskreutz, Vice President and Head of Global Marketing for Merz. “With the launch of Belotero® Lips Shape and Contour, Merz is proud to now offer physicians a unique complementary approach to lip enhancement.”
Modern female consumers already know what it means to “get their lips done.” As a result they have high expectations: results need to be natural, long-lasting and comfortable, and lip treatment is seen as a way to show off their own enhanced yet unique beauty. Just as lipstick and lipliner complement each other, Belotero® Lips Shape and Belotero® Lips Contour provide volume and definition for patient-specific, optimized results. Belotero® Lips Shape is intended for lip augmentation and enhancing the upper and lower lip, while Belotero® Lips Contour is designed to define the outline of the lip.
“Full, well-defined lips are a key signature of youth and beauty. That is why in my practice, I often see patients looking to enhance their smile and to address the signs of aging in this crucial area of the face,” said Dr. Uliana Gout, Cosmetic Doctor and Founder of London Aesthetic Medicine, UK. “Belotero® Lips is positioned for good tissue integration, delivery of high patient satisfaction and natural-looking results for all ages. Due to the extra versatility offered by the Belotero® Lips concept, with products specifically designed for both shaping and contouring, this allows for a tailored lip treatment for our patients.”
Lip augmentation using Belotero® Lips Shape and Belotero® Lips Contour was clinically assessed in a retrospective, multicenter study involving 146 patients.2 Observation period took place over 4 months, with assessment of handling and treatment results. For CPM-HAL2, the outcome with regard to naturalness and evenness after 2 weeks was assessed by the vast majority as very good (87%). This very good assessment was still maintained for 66.7% of patients after 4 months. The most common side effects observed following lip treatment with Belotero® were: swelling, tenderness, bruising, pain and redness. The majority of these side effects were mild and have also been observed in other lip enhancement clinical trials. Belotero® Lips Shape and Belotero® Lips Contour should only be administered by a physician or qualified healthcare professional.
Belotero® Lips products are now available in select countries in Europe, with additional markets to be added later this year. For more details, please visit https://global.belotero.com/ or follow @Merz_Aesthetics on Instagram .
About Merz
With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned medical aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, solid financial strength and continuous growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com .
1 Sarnoff DS, Gotkin RH. Six steps to the “perfect” lip. J Drugs Dermatol. 2012 Sep;11(9):1081-8.
2 Fischer TC, et al. Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience. Facial Plast Surg. 2016 Jun;32(3):283-8.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005702/en/
Contact:
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana
Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom